Get started

Investment

Can 128% be soon?Cardano (ADA) is one of my favourite coins which I choose to invest in. This is trade (investment) setup on larger timeframe. If you never bought ADA before it is still not late. I am not looking to reach targets 2,3,4 very soon, that could be year(s). I will sell most of my capital on targets 2,3. Small portion will be sold on Target 1 and hopefully on Target 4. Entry Zone: 0.50 – 0.57 Buy Zone 1: 0.30 – 0.37 Buy Zone 2: 0.13 – 0.16 Target 1: 1.33 – 1.44 (128%) Target 2: 2.83 – 2.93 (390%) Target 3: 4.35 – 4.89 (651%) Target 4: 5.73 – 5.84 (891%)
Long
by Abmoon
6
Concerned about aging? Start investing in Addus now!The aging U.S. population is set to double by 2050, increasing the need for caregivers. Addus HomeCare Corporation, based in Frisco, Texas, provides essential personal care, hospice, and home health services. With a market cap of $2.35 billion, Addus reported $1.115 billion in revenue in June 2024, with a 27% profit increase. The company is debt-free and has major shareholders like Blackrock and The Vanguard Group. EPS is forecasted to grow significantly by December 2025. With a growing need for home healthcare services, the company is well-positioned to expand its customer base and market presence. Company Overview Addus HomeCare Corporation and its subsidiaries offer personal care services for the elderly, disabled, and those at risk of hospitalization in the U.S. It operates in three areas: Personal Care, Hospice, and Home Health. The Personal Care segment helps with daily activities like bathing, grooming, and meal preparation. The Hospice segment provides care and support for terminally ill patients and their families. The Home Health segment delivers skilled nursing and therapy services for those recovering from illness or hospitalization. Its clients include government agencies, managed care organizations, insurers, and private individuals. Founded in 1979, Addus is based in Frisco, Texas. Investment Advice by Naranj Capital Buy Addus Homecare Corporation NASDAQ:ADUS ● Buy Range- 120 - 125 ● Target- 150 - 160 ● Potential Return- 25-30% ● Duration- 10 -12 Months Market Capitalization - $ 2.35B Sector - Healthcare (Nursing) Technical Analysis ● The monthly chart indicates a clear upward trend in prices. ● Earlier, the stock peaked near the 129 (128.8 to be precise) level before experiencing a correction, which was subsequently followed by an elongated consolidation period from November 2020 to July 2024. ● Recently, the stock has successfully made a multi-year breakout of the previous resistance zone and has maintained its position above this breakout level. ● We expect this momentum to persist, leading to further price increases in the days ahead. Entry, Exit & Stop-loss ● Entry with Capital allocation strategy (1) consider adding 50% of your desired quantity at the current market price (132 - 133). (2) The second buying opportunity will be in the 120 - 122 range, where you can also add rest 50% of your quantity. ● Target Chart analysis indicates a promising upside potential of 25-30% for this stock from the best buying level, with a target around the 155 to 160. There is also a strong likelihood that the stock could exceed this target. ● Stoploss It is crucial to implement a strict stop-loss below the 115 level, as we anticipate that the stock may encounter challenges if it drops to this point. Revenue Breakdown The company generates its revenue through three primary segments. (1) The personal care sector represents around 74.2% of the overall revenue, totaling $827 million out of $1.11 billion. (2) Meanwhile, hospice services contribute nearly 19.7%, amounting to $219.8 million of the total revenue. (3) The home health segment accounts for approximately 6.1%, which translates to $67.8 million of the overall revenue. Sales & Profit Analysis ● A noticeable rise in revenue has been observed. For the June quarter, revenue reached $1.115 billion, marking an 11.6% increase from $999 million in June 2023 (YoY) and a 2.5% rise from $1.08 billion in March 2024 (QoQ). ● Additionally, profits surged by 27% in the latest quarter, climbing to $68.89 million from $53.83 million in the same quarter last year, and up 5% from $65.67 million in March 2024. ● The profit margin has also improved, increasing from 5.4% to 6.2% year-on-year. ● The basic EPS for the June 2024 quarter is reported at 4.28, marking a significant increase of 27% from 3.37 in the same quarter last year. Peer Companies (1) Privia Health Group (NASDAQ: PRVA) - $ 2.41B NASDAQ:PRVA (2) Amedisys (NASDAQ: AMED) - $ 3.21B NASDAQ:AMED (3) Astrana Health (NASDAQ: ASTH) - $ 2.33B NASDAQ:ASTH Valuation ● P/E vs Fair P/E Ratio ➖ The current PE ratio stands at 34.1x, slightly expensive to the estimated Fair PE of 28.7x. ● P/E Ratio vs Peers ➖ ADUS offers great value with a Price-To-Earnings Ratio of 34.1x, significantly lower than the peer average of 62.7x. ● P/E Ratio vs Industry P/E ➖ ADUS seems to come at a higher price, boasting a Price-To-Earnings Ratio of 34.1x, notably surpassing the US Healthcare industry average of 26.2x. Debt Analysis ➖ ADUS stands proudly as a debt-free entity, a remarkable transformation from five years ago when its debt to equity ratio stood at 12.9%. This significant shift underscores the company's commitment to financial health and stability. Top Shareholders ● Blackrock currently holds a substantial 16% stake in this stock, reflecting an impressive increase of 11.2% since the March quarter. ● Meanwhile, The Vanguard Group has also boosted its investment, raising its stake by 8.5% from the previous quarter, bringing their total holding to 7.74%. Earnings per Share Growth Forecasts Experts forecast that the earnings per share (EPS) could increase from $4.28 to $4.51 by December 2024, and further rise to $5.03 by December 2025. Conclusion With the growing need for home healthcare services, the company is well-positioned to broaden its customer base and enhance its market presence.
NASDAQ:ADUSLong
by NaranjCapital
1
NASDAQ: ATPC Spiked 65% Pre-Market Upon Successful Reverse Stock Agape ATP Corporation (ATPC) saw an impressive 65% spike in pre-market trading today, a clear indication of investor confidence following the company’s recent 20:1 reverse stock split. This strategic move appears to have paid off, significantly boosting the stock price and attracting renewed interest from both institutional and retail investors. The reverse stock split, which consolidated shares to enhance market stability and meet Nasdaq listing requirements, has evidently strengthened ATPC’s market position, setting the stage for further growth in the renewable energy sector. Investors are now eyeing ATPC as a promising player in the green energy landscape, with the recent price surge reflecting growing optimism about the company's future prospects. As the renewable energy sector continues to gain momentum, ATPC's strategic decisions, including this reverse split, are likely to play a crucial role in its long-term success.
NASDAQ:ATPCLong
by HASHInvests200
Good time to buy and HODL!Arweave (AR) is one of my recent coins which I choose to invest in. This is trade (investment) setup on larger timeframe. I am not looking to reach targets 2,3,4 and 5 very soon, that could be year(s). I will sell most of my capital on targets 2,3. Small portion will be sold on Target 1 and on Target 4 and 5. Entry Zone: 9.07 – 11.07 Buy Zone 1: 6.06 – 7.36 Target 1: 26.03 – 28.75 (135%) Target 2: 38.39 – 42.25 (247%) Target 3: 56.98 – 60.36 (432%) Target 4: 75.92 – 78.98 (609%) Target 5: 93.40 – 99.77 (774%)
Long
by Abmoon
16
Apple (AAPL): Swing Entry on the HorizonLast time, we narrowly missed the entry on Apple by just a few dollars, and after that miss, the stock no longer presented a compelling opportunity, so we decided to wait. However, after observing from the sidelines for a few months, it seems that another chance to secure a profitable swing entry might be approaching. To increase our confidence in this potential opportunity and secure a better entry point, we need to closely monitor further movements from this tech giant. The current price action strongly suggests that a flat pattern might be forming following the recent drop. If this flat pattern does materialize, it could manifest as either a regular flat or an expanded flat, and this will be crucial in determining our entry target zone. At this stage, the area between $200 and $180 seems the most probable and attractive for a potential entry. Given the broader market trends and Apple’s recent performance, this zone could offer a favorable risk-reward ratio. We’ll be watching for any developments that confirm this pattern and provide a clearer signal for entry. Stay tuned for further updates as we refine our strategy and prepare for a possible move on Apple.
NASDAQ:AAPLLong
by freeguy_by_wmc
S&P 500 Daily Chart Analysis For Week of Aug 23, 2024Technical Analysis and Outlook: Throughout the current week's trading session, the S&P 500 Index has demonstrated notable resilience, surpassing the Mean Resistance level of 5564 and positioning itself beneath the attained Inner Index Rally at 5666. The prevailing price action indicates a sustained upward momentum aimed at retesting the completed Interim Index Rally at 5666, with an eye on the subsequent upside objectives represented by the Inner Index Rally at 5745 and the ultimate Outer Index Rally at 5840. It is important to note that the attainment of these targets is likely to prompt a selling price action.
SP:SPX
by TradeSelecter
Sanofi (SNY): A Strong Investment CaseCompany Overview: Sanofi NASDAQ:SNY is a major pharmaceutical company based in Paris, with a market capitalization of $134 billion. Investment Highlights: Dividend Yield: 3.8%, more than double the S&P 500 average. Drug Portfolio: Diverse and includes successful drug developments. Pipeline: Promising future drug pipeline with potential for growth. Berkshire Hathaway Investment: Long-standing investment from Berkshire Hathaway underscores the company’s attractiveness and stability. Outlook: We are bullish on SNY due to its growth potential and solid dividend payout. The combination of a strong drug portfolio, promising pipeline, and robust dividend makes Sanofi a compelling investment choice. #Sanofi #SNY #Pharmaceuticals #Investment #DividendYield #MarketCap #GrowthPotential #BerkshireHathaway #StockAnalysis #Bullish
NASDAQ:SNYLong
by Richtv_official
Chevron (CVX): Approaching a Critical Support ZoneIt's been a while since we last analyzed CVX, but we’re now approaching a very important area on the chart. You might wonder why we’re focusing on the weekly chart instead of the daily. The reason is simple: sometimes you need to zoom out to get a clearer perspective, and in this case, the weekly chart holds far more significance than the daily. There’s no point in searching for entries on the daily when the more crucial entry level on the weekly is just below. We’re looking to find support at the HVN POC (High Volume Node Point of Control) at $117, which would also serve as a retest after the last breakout in 2022. We’re still determining the best way to place a limit order at this level, but for now, we’re waiting on the sidelines with alerts set and a light game plan ready.
NYSE:CVXLong
by freeguy_by_wmc
Target (TGT): Ready to Break Out of Its DowntrendWith Target, we have another major player in the US retail market, and we prefer its price structure over Walmart's. After completing Wave (3), Target experienced a significant sell-off, forming Wave (4). Currently, it appears that an inverse head and shoulders pattern is developing, which could signal a bullish reversal. The neckline looks particularly strong, and I will have a bullish outlook once this neckline is reclaimed. There is a breakout gap following the completion of Wave (4), which might be revisited. However, for a well-formed head and shoulders pattern, we should see some momentum soon to create two shoulders at the same level. As long as the Wave (4) level at the Point of Control (POC) holds, we expect more upside, either after a slight dip into the breakout gap or immediately following the earnings report next week.
NYSE:TGTLong
by freeguy_by_wmc
3
Cisco (CSCO): Ready for a Post-Earnings Drop?As we approach Cisco's earnings report, it's time for another pre-earnings analysis. We're examining both the higher time frame and then zooming in for a closer look. On the higher time frame (Daily), Cisco is following a nearly perfect trend channel. While a retest of the lower range of this trend channel seems the most probable, I suspect that the price could breach this level and wick into our target zone between $38 and $32. If this scenario unfolds as anticipated, it could present a great opportunity to take a long position in Cisco, potentially holding into 2025 for more significant gains. The bearish outlook is further supported by a shoulder-head-shoulder formation that has caught our eye. Although we typically don't trade based on these formations, this one is hard to ignore. Ideally, we'd see a breach below the lower trend channel range, followed by a retest, and then a sell-off into our target zone. We're watching closely for the first signs of movement following Wednesday's earnings report.
NASDAQ:CSCO
by freeguy_by_wmc
Electronic Arts (EA) | Finally a Confirmed Breakout!Hi, Electronic Arts (EA) has finally made a statement. For over 6 years it has tried to break above $150. Multiple failed attempts before the 2024 July close which was the confirmation for a possible further growth. This is a perfect example of how you should wait for a breakout. Let the other investors show you what might happen next. They were willing to pay prices that have never been paid per share and we take it as a strong statement, monthly close is the confirmation, and who want to jump in then there is the possibility. Quite a similar price action to my earlier post about Mastercard (MA): Good luck, Vaido
NASDAQ:EALong
by VaidoVeek